Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENRAPRED: Predictive Signature of Benralizumab Response
NCT04565483Phase 4Recruiting
- Sponsor
- CHU de Nantes
- Start
- Oct 2021
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of benralizumab in eosinophilic asthma (EA), sponsored by CHU de Nantes. Started Oct 2021; status: recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04565483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565483.